Dariohealth Corp. (DRIO) closed at $1.46 on November 18, 2026, up 27.0% from the previous close, on volume of 109,811 shares (30-day average 66,751).
Data as of November 18, 2026.
Dario Secures Second Women's Health Contract in Just Weeks with The Minnesota Star Tribune
PRNewswire (Wed, 18-Nov 7:30 AM ET)
PRNewswire (Mon, 16-Nov 7:30 AM ET)
DarioHealth Earnings Call Signals Growth and 2028 Breakeven
TipRanks (Sat, 14-Nov 11:19 PM ET)
/C O R R E C T I O N - DarioHealth Corp./
PRNewswire (Thu, 12-Nov 10:02 AM ET)
PRNewswire (Thu, 12-Nov 6:30 AM ET)
PRNewswire (Wed, 4-Nov 7:30 AM ET)
DarioHealth to Report Third Quarter 2026 Results on Thursday, November 12, 2026
PRNewswire (Mon, 2-Nov 8:30 AM ET)
DarioHealth targets 19,000-employee retailer expansion as Dario Women rolls out in January 2027
Market Chameleon (Mon, 26-Oct 7:27 AM ET)
PRNewswire (Mon, 26-Oct 8:30 AM ET)
PRNewswire (Tue, 6-Oct 7:30 AM ET)
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
Dariohealth Corp. trades on the NASDAQ stock market under the symbol DRIO.
As of November 18, 2026, DRIO stock price climbed to $1.46 with 109,811 million shares trading.
DRIO has a beta of -0.56, meaning it tends to be less sensitive to market movements. DRIO has a correlation of 0.01 to the broad based SPY ETF.
DRIO has a market cap of $16.48 million. This is considered a Sub-Micro Cap stock.
Last quarter Dariohealth Corp. reported $5 million in Revenue and -$.47 earnings per share. This beat revenue expectation by $104,400 and exceeded earnings estimates by $.07.
In the last 3 years, DRIO traded as high as $52.00 and as low as $1.09.
The top ETF exchange traded funds that DRIO belongs to (by Net Assets): VXF, IWC, DCOR, DFSU, DFMC.
DRIO has underperformed the market in the last year with a price return of -89.5% while the SPY ETF gained +10.8%. DRIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -80.2% and -51.3%, respectively, while the SPY returned -5.3% and -3.2%, respectively.
DRIO support price is $1.01 and resistance is $1.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRIO shares will trade within this expected range on the day.